CA3266104A1 - Compositions and methods for delivery of rna - Google Patents
Compositions and methods for delivery of rnaInfo
- Publication number
- CA3266104A1 CA3266104A1 CA3266104A CA3266104A CA3266104A1 CA 3266104 A1 CA3266104 A1 CA 3266104A1 CA 3266104 A CA3266104 A CA 3266104A CA 3266104 A CA3266104 A CA 3266104A CA 3266104 A1 CA3266104 A1 CA 3266104A1
- Authority
- CA
- Canada
- Prior art keywords
- rna
- delivery
- compositions
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Manufacturing & Machinery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263402195P | 2022-08-30 | 2022-08-30 | |
| PCT/US2023/073104 WO2024050372A2 (en) | 2022-08-30 | 2023-08-29 | Compositions and methods for delivery of rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3266104A1 true CA3266104A1 (en) | 2024-03-07 |
Family
ID=90098696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3266104A Pending CA3266104A1 (en) | 2022-08-30 | 2023-08-29 | Compositions and methods for delivery of rna |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4580609A2 (en) |
| JP (1) | JP2025529173A (en) |
| CN (1) | CN119789852A (en) |
| AU (1) | AU2023334154A1 (en) |
| CA (1) | CA3266104A1 (en) |
| IL (1) | IL319195A (en) |
| WO (1) | WO2024050372A2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022173531A1 (en) * | 2021-02-10 | 2022-08-18 | Oncorus, Inc. | Compounds, compositions, and methods of using thereof |
-
2023
- 2023-08-29 EP EP23861498.6A patent/EP4580609A2/en active Pending
- 2023-08-29 CN CN202380062898.2A patent/CN119789852A/en active Pending
- 2023-08-29 JP JP2025512840A patent/JP2025529173A/en active Pending
- 2023-08-29 AU AU2023334154A patent/AU2023334154A1/en active Pending
- 2023-08-29 WO PCT/US2023/073104 patent/WO2024050372A2/en not_active Ceased
- 2023-08-29 CA CA3266104A patent/CA3266104A1/en active Pending
- 2023-08-29 IL IL319195A patent/IL319195A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL319195A (en) | 2025-04-01 |
| EP4580609A2 (en) | 2025-07-09 |
| CN119789852A (en) | 2025-04-08 |
| WO2024050372A2 (en) | 2024-03-07 |
| JP2025529173A (en) | 2025-09-04 |
| AU2023334154A1 (en) | 2025-03-06 |
| WO2024050372A3 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2605312B (en) | Compositions and methods for delivery of RNA | |
| GB2613225B (en) | Compositions and methods for targeted RNA delivery | |
| CA3249292A1 (en) | Compositions and methods for delivery of nucleic acids | |
| IL304123A (en) | Compositions and methods for delivery of rna | |
| EP4117684A4 (en) | Compositions and methods for enhanced delivery of antiviral agents | |
| EP4240248A4 (en) | Compositions and methods for targeted delivery of therapeutics using carriers | |
| IL316504A (en) | Rna compositions for delivery of monkeypox antigens and related methods | |
| AU2021413753A9 (en) | Compositions and methods for delivery of rna | |
| EP3788141A4 (en) | Compositions and therapeutic methods of microrna gene delivery | |
| EP4415690A4 (en) | Compositions and methods for delivery of agents | |
| IL288542A (en) | Methods and compositions for microbial delivery of double stranded rna | |
| CA3266104A1 (en) | Compositions and methods for delivery of rna | |
| HK40101750A (en) | Compositions and methods for delivery of rna | |
| HK40099690A (en) | Compositions and methods for delivery of rna | |
| CA3256767A1 (en) | Gene therapy compositions and methods of use thereof | |
| IL318499A (en) | Compositions for targeted lysosomal degradaton and methods of use thereof | |
| IL316049A (en) | Pharmaceutical compositions of mosunetuzumab and methods of use | |
| EP4352218A4 (en) | Compositions and methods for targeted delivery of therapeutic agents | |
| GB202319290D0 (en) | Compositions and methods of gene expression | |
| GB202319294D0 (en) | Compositions and methods of gene expression | |
| HK40112368A (en) | Compositions and methods for targeted rna delivery | |
| CA3265882A1 (en) | Methods and compositions for hydrodynamic gene delivery | |
| AU2024299365A1 (en) | Compositions for delivery of plasmodium antigens and related methods | |
| AU2024301077A1 (en) | Compositions for delivery of plasmodium antigens and related methods | |
| HK40103646A (en) | Compositions for and methods of improving gene therapy |